Treatment of allergic bronchopulmonary mycosis: Experience of 55 patients with 124 relapses—A descriptive study

Ishiguro, Takashi; Kojima, Ayako; Takata, Naomi; Takayanagi, Noboru

doi:10.1002/ccr3.2305

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was in addition a significantly higher number of patients with steroid-related complications in the higher dose group. 76 A recent review by Ishiguro et al 77 into patients with ABPM showed that systemic corticosteroids are also effective in this related condition. Intravenous pulsed steroids have been studied and shown to be beneficial in children with refractory ABPA exacerbations associated with long-term steroid use.…”

Section: Current and Future Therapiesmentioning

confidence: 99%

Review of current and future therapeutics in ABPA

Lewington-Gower

Chan

2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Allergic bronchopulmonary aspergillosis is an allergic pulmonary condition caused by hypersensitivity to antigens of Aspergillus sp. found most commonly in patients with underlying asthma or cystic fibrosis. Host factors which alter the innate and adaptive immune responses to this abundant airborne fungus contribute to the development of chronic airway inflammation, bronchiectasis, and fibrosis. Traditionally, treatment has focussed on reducing fungal burden and immune response to fungal antigens. However, a significant proportion of patients continue to suffer recurrent exacerbations with progressive lung damage, and the side effect burden of existing treatments is high. New treatments including novel antifungal agents, monoclonal antibodies against aspects of the adaptive immune response as well as targeted immunotherapies may be better tolerated and achieve improved outcomes but have not yet been studied in large-scale randomised control trials.

show abstract

Section: Current and Future Therapiesmentioning

confidence: 99%

Review of current and future therapeutics in ABPA

Lewington-Gower

Chan

2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

Allergic bronchopulmonary mycosis due to Talaromyces marneffei: The first case report

Wang,

Zhan,

et al. 2024

Preprint

View full text Add to dashboard Cite

Allergic bronchopulmonary mycosis (ABPM) is a hypersensitivity disease of the lower airways caused by environmental fungi. While Aspergillus fumigatus is the most common pathogen, there has been a gradual increase in the occurrence of ABPM caused by other fungi in the past 20 years. This case report presents the first case of ABPM associated with Talaromyces marneffei (TM). The patient had positive TM results on bronchoalveolar lavage fluid (BALF) culture and multiple metagenomic next-generation sequencing (mNGS), a total IgE level of 1155 IU/ml, an IgG antibody to Aspergillus level (> 500 AU/ml) that was considerably higher than normal, and CT with central bronchiectasis and mucous embolus. Combined with the patient's clinical symptoms, the diagnosis was TM-related ABPM. Subsequently, the patient achieved favourable therapeutic effects through oral corticosteroid treatment. This case shows us the possibility of noninvasive infection of TM in the lower respiratory tract, improves our understanding of ABPM, and provides a reference for the clinical diagnosis and treatment of the disease.

show abstract

Treatment of allergic bronchopulmonary mycosis: Experience of 55 patients with 124 relapses—A descriptive study

Cited by 2 publications

References 26 publications

Review of current and future therapeutics in ABPA

Review of current and future therapeutics in ABPA

Allergic bronchopulmonary mycosis due to Talaromyces marneffei: The first case report

Contact Info

Product

Resources

About